Hospira launching Remicade biosimilar in EU; India drug market shrinks;

@EricPFierce: Another gut check for Amarin and its fish oil drug  panel votes against wider use. News | Follow @EricPFierce

> Hospira ($HSP) is readying the European launch of its biosimilar of Johnson & Johnson's ($JNJ) rheumatoid arthritis treatment Remicade. Story

> Hospira is voluntarily recalling one lot of metoclopramide injection, USP, and two lots of ondansetron injection, USP, after identifying glass strands in the wall of some vials due to a supplier defect. Release

> India recorded a 1.8% decline in its domestic pharmaceutical manufacturing business in September, the first retreat, led by a 14% drop in those drugs now price-controlled. Story

> CMC Biologics has had its Good Manufacturing Practice (cGMP) certification renewed by the Danish Medicines Agency (DKMA) for a facility in Copenhagen following improvements to the facility. Release

And Finally... Johnson & Johnson ($JNJ) says it will stop using formaldehyde in the manufacture of baby shampoo. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.